Skip to content

Study · In vitro (cells) · 1999

2 results

Cell cycle arrest in endometrial carcinoma cells exposed to gonadotropin-releasing hormone analog.

Kim JW, Lee YS, Kim BK, Park DC, Lee JM, Kim IK, Namkoong SE

Gynecologic oncology1 Jun 1999Cited by 15 (Europe PMC)

PMID10366462 (opens in a new tab)DOI10.1006/gyno.1999.5398 (opens in a new tab)PepBankPUB-10366462
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human endometrial carcinoma cells, D-Trp6-LHRH induced cell cycle arrest at the G1-S transition.

    In plain wordsIn cells from human endometrial cancer, D-Trp6-LHRH caused cell cycle arrest at the G1-S transition.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseG1-S cell cycle arrest
    Study

    humann: not reported in source

    GnRH receptor-expressing endometrial cancer cell line
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    10 microM · 36 hAs given in this study (human).

    Source sentences

    Summary
    Flow cytometric analysis revealed that cultured carcinoma cells showed a cell cycle arrest at the G1-S transition after treatment with 10 microM D-Trp6-LHRH for 36 h.
    1 context sentence
    Summary · context
    We have treated a human endometrial cancer cell line which expresses GnRH receptor with GnRH analog, D-Trp6-LHRH, in order to study whether there are differences in cell cycle kinetic response.
  2. 02LabIn vitro (cells)Mechanism

    In human endometrial carcinoma cells, p16 protein was evident after D-Trp6-LHRH treatment.

    In plain wordsIn cells from human endometrial cancer, p16 protein was evident after D-Trp6-LHRH treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicablep16 protein detection
    Study

    humann: not reported in source

    GnRH receptor-expressing endometrial cancer cell line
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated · 24 hAs given in this study (human).

    Source sentences

    Summary
    Western blot analysis showed that the level of p16 protein was obvious following 24 h of D-Trp6-LHRH treatment.
    1 context sentence
    Summary · context
    We have treated a human endometrial cancer cell line which expresses GnRH receptor with GnRH analog, D-Trp6-LHRH, in order to study whether there are differences in cell cycle kinetic response.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.